Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Emerging patent issues in genomic diagnostics

John H Barton¹

¹Stanford Law School, Crown Quadrangle, 559 Nathan Abbott Way, Stanford University, Stanford, CA 94305-8610, USA. jbarton@stanford.edu

Nature Biotechnology

|August 11, 2006

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric Adenocarcinomas.

The oncologist·2017

Same author

A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.

Cancer chemotherapy and pharmacology·2016

Same author

Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2010

Same author

Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.

Cancer investigation·2010

Same author

A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.

Clinical breast cancer·2008

Same author

A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.

Clinical breast cancer·2008